A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
NCT ID: NCT07096674
Last Updated: 2025-08-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
90 participants
INTERVENTIONAL
2025-08-12
2026-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
NCT06752668
A Study of ORX142 in Healthy Adult Subjects, Including Subjects 18 to 80 Years of Age
NCT07082829
A Study to Evaluate the Safety and Efficacy of TS-091 in Patients with Narcolepsy
NCT03267303
A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
NCT06767683
Effect of Intranasal Administration of Orexine A on IL-6-System, Sleep-Wake-Regulation and Neurocognition
NCT00484757
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Narcolepsy Type 1
Narcolepsy Type 1 (Open Label)
ORX750
Oral ORX750
Narcolepsy Type 2
Narcolepsy Type 2 (Open Label)
ORX750
Oral ORX750
Idiopathic Hypersomnia
Idiopathic Hypersomnia (Open Label)
ORX750
Oral ORX750
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ORX750
Oral ORX750
ORX750
Oral ORX750
ORX750
Oral ORX750
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Is willing and able to adhere to additional protocol requirements
Exclusion Criteria
* Unable to refrain from excluded medications, including those used for treatment of narcolepsy or idiopathic hypersomnia
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centessa Pharmaceuticals (UK) Limited
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Site Number 1
Huntersville, North Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ORX750-202
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.